Understanding Indolent B-cell NHL That Has Progressed and Treatment With TREANDA

This Web site will help you understand your disease and TREANDA. It will give you some information about indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within 6 months of rituximab or a rituximab-containing regimen, how to take TREANDA, and what you can expect from using it, including side effects.

To learn more about non-Hodgkin lymphoma, a name given to some kinds of cancers that start with cells that help fight disease, click here. To learn more about the different types of NHL, click here. And to learn more about treatment options for CLL, click here.

TREANDA is FDA-approved for the treatment of indolent B-cell NHL that has progressed. TREANDA is a chemotherapy that has been shown to kill cells that cause indolent B-cell NHL. The exact way in which TREANDA kills cells is still being studied in laboratories. In a clinical study, patients with a form of indolent B-cell NHL who had previously received treatment with rituximab received TREANDA only. For more information about the study results for TREANDA, click here.

The most common non-blood-related side effects (occurring in ≥15% of patients) with TREANDA are nausea, fatigue, vomiting, diarrhea, pyrexia (fever), constipation, anorexia (loss of appetite), cough, headache, weight decreased, dyspnea (difficulty breathing), rash, and stomatitis (inflammation of the mouth).

The most common blood-related side effects (occurring in ≥15% of patients) with TREANDA are reduction of lymphoid cells in the blood (lymphopenia), low counts of leukocytes (white blood cells) (leukopenia), reduction of red blood cells (anemia), reduction of neutrophils (white blood cells) (neutropenia), and reduction of blood platelets (thrombocytopenia).

> Next section: Understanding NHL

The information given in this Web site is not meant to take the place of speaking with your doctor and healthcare team about your disease or its treatment. If you have any questions, you should talk about them with your healthcare team.

Indications

TREANDA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established.

TREANDA is indicated for the treatment of patients with indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen.

Important Safety Information

• The most common non-blood-related side effects (occurring in ≥15% of patients) with TREANDA are nausea, fatigue, vomiting, diarrhea, pyrexia (fever), constipation, anorexia (loss of appetite), cough, headache, weight decreased, dyspnea (difficulty breathing), rash, and stomatitis (inflammation of the mouth)
• The most common blood-related side effects (occurring in ≥15% of patients) with TREANDA are reduction of lymphoid cells in the blood, low counts of leukocytes (white blood cells), reduction of red blood cells, reduction of neutrophils (white blood cells) and reduction of blood platelets
• Allergic Reactions: There is a possibility of mild or serious allergic reactions with TREANDA. Immediately report rash, facial swelling, or difficulty breathing during or soon after infusion because these symptoms may become severe or even life-threatening
• Myelosuppression: TREANDA may cause a decrease in white blood cells, platelets, and red blood cells. You will need frequent monitoring of your blood cells. Report shortness of breath, significant fatigue, bleeding, fever, or other signs of infection because these symptoms may become severe or even life-threatening
• Pregnancy and Nursing: TREANDA can cause fetal harm. Women should avoid becoming pregnant throughout treatment and for 3 months after TREANDA therapy has stopped. Men receiving TREANDA should use reliable contraception for the same time period. Report pregnancy immediately. Avoid nursing while receiving TREANDA
• Fatigue: TREANDA may cause tiredness. Avoid driving any vehicle or operating any dangerous tools or machinery if you experience this side effect
• Nausea and Vomiting: TREANDA may cause nausea and/or vomiting. You should report nausea and vomiting to your doctor so that you can get treatment for these symptoms
• Diarrhea: TREANDA may cause diarrhea. You should report diarrhea to your doctor so that it can be treated
• Rash: A mild rash or itching may occur during treatment with TREANDA. Immediately report severe or worsening rash or itching to your doctor
• Some side effects may lead to the dose of TREANDA being lowered, stopped, or delayed
• You should not take TREANDA if you have a known allergy to bendamustine or mannitol